ClinicalTrials.gov
ClinicalTrials.gov Menu

Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01141595
Recruitment Status : Completed
First Posted : June 10, 2010
Results First Posted : February 24, 2014
Last Update Posted : April 1, 2014
Sponsor:
Collaborator:
BioMarin Pharmaceutical
Information provided by (Responsible Party):
Richard Frye, Arkansas Children's Hospital Research Institute

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Autism Spectrum Disorder
Intervention: Drug: sapropterin dihydrochloride

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
All patients were recruited from a medical clinic specalizing in neurodevelopmental disorders

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No significant events

Reporting Groups
  Description
Kuvan® Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.

Participant Flow:   Overall Study
    Kuvan®
STARTED   10 
COMPLETED   8 
NOT COMPLETED   2 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Kuvan® Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.

Baseline Measures
   Kuvan® 
Overall Participants Analyzed 
[Units: Participants]
 10 
Age 
[Units: Participants]
 
<=18 years   10 
Between 18 and 65 years   0 
>=65 years   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 5.0  (1.2) 
Gender 
[Units: Participants]
 
Female   1 
Male   9 
Region of Enrollment 
[Units: Participants]
 
United States   10 


  Outcome Measures

1.  Primary:   Preschool Language Scales   [ Time Frame: 16 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Richard Frye
Organization: Arkansas Children's Hospital Reseach Insitute
phone: 501-364-5465
e-mail: REFrye@uams.edu


Publications of Results:
Other Publications:

Responsible Party: Richard Frye, Arkansas Children's Hospital Research Institute
ClinicalTrials.gov Identifier: NCT01141595     History of Changes
Other Study ID Numbers: HSC-MS-09-0578
First Submitted: June 8, 2010
First Posted: June 10, 2010
Results First Submitted: January 15, 2013
Results First Posted: February 24, 2014
Last Update Posted: April 1, 2014